APTUS HELI-FX AORTIC SECUREMENT SYSTEM

K130677 · Aptus Endosystems, Inc. · OTD · Apr 12, 2013 · Cardiovascular

Device Facts

• Record ID: K130677
• Device Name: APTUS HELI-FX AORTIC SECUREMENT SYSTEM
• Applicant: Aptus Endosystems, Inc.
• Product Code: OTD · Cardiovascular
• Decision Date: Apr 12, 2013
• Decision: SESE
• Submission Type: Special
• Regulation: 21 CFR 870.3460
• Device Class: Class 2
• Attributes: Therapeutic

Intended Use

The Heli-FX Aortic Securement System is intended to provide fixation and sealing between endovascular aortic grafts and the native artery. The Heli-FX System is indicated for use in patients whose endovascular grafts have exhibited migration or endoleak, or are at risk of such complications, in whom augmented radial fixation and/or sealing is required to regain or maintain adequate aneurysm exclusion. The EndoAnchor may be implanted at the time of the initial endograft placement, or during a secondary (i.e., repair) procedure.

Device Story

System provides mechanical fixation between endovascular aortic grafts and native artery; comprises EndoAnchor implants, Heli-FX Applier, and Heli-FX Guide. EndoAnchor is helical nickel-cobalt wire acting as suture; Applier is 12Fr catheter for delivery; Guide is deflectable sheath for positioning. Used in clinical/OR setting by physicians. Applier delivers anchors through graft into vessel wall to prevent migration/endoleak. Benefits patient by securing graft and maintaining aneurysm exclusion. No software or AI components.

Clinical Evidence

Bench testing only. Performance, simulated use, and mechanical characterization testing demonstrated substantial equivalence.

Technological Characteristics

Components: EndoAnchor (nickel-cobalt wire), Heli-FX Applier (12Fr catheter), Heli-FX Guide (deflectable sheath, 12Fr-compatible, 62cm/90cm lengths). Mechanical fixation principle. Sterile, single-use. No software, electronics, or energy sources.

Indications for Use

Indicated for patients with endovascular aortic grafts exhibiting or at risk of migration or endoleak requiring augmented radial fixation or sealing to maintain aneurysm exclusion. May be used during initial endograft placement or secondary repair.

Regulatory Classification

Identification

An endovascular suturing system is a medical device intended to provide fixation and sealing between an endovascular graft and the native artery. The system is comprised of the implant device and an endovascular delivery device used to implant the endovascular suture.

Special Controls

*Classification.* Class II (special controls). The special controls for this device are:(1) The device should be demonstrated to be biocompatible; (2) Sterility and shelf life testing should demonstrate the sterility of patient-contacting components and the shelf-life of these components; (3) Non-clinical and clinical performance testing should demonstrate substantial equivalence in safety and effectiveness, including durability, compatibility, migration resistance, corrosion resistance, and delivery and deployment; (4) Non-clinical testing should evaluate the compatibility of the device in an magnetic resonance (MR) environment; (5) Appropriate analysis and non-clinical testing should validate electromagnetic compatibility (EMC) and electrical safety; (6) The sale, distribution, and use of the device are restricted to prescription use in accordance with 21 CFR 801.109 of this chapter; and (7) Labeling must bear all information required for the safe and effective use of the device as outlined in § 801.109(c) of this chapter, including a detailed summary of the non-clinical and clinical evaluations pertinent to use of the device.

In addition to the general controls of the Food, Drug & Cosmetic Act, the Endovascular Suturing System is subject to the following special controls: (1) The device should be demonstrated to be biocompatible; (2) Sterility and shelf life testing should demonstrate the sterility of patient-contacting components and the shelf-life of these components; (3) Non-clinical and clinical performance testing should demonstrate substantial equivalence in safety and effectiveness, including durability, compatibility, migration resistance, corrosion resistance, and delivery and deployment; (4) Non-clinical testing should evaluate the compatibility of the device in an MR environment; (5) Appropriate analysis and non-clinical testing should validate electromagnetic compatibility (EMC) and electrical safety; (6) The sale, distribution, and use of the device are restricted to prescription use in accordance with 21 CFR 801.109; and (7) Labeling must bear all information required for the safe and effective use of the device as outlined in 801.109(c), including a detailed summary of the non-clinical and clinical evaluations pertinent to use of the device.

Predicate Devices

• Aptus Heli-FX Aortic Securement System (K102333)
• Aptus Heli-FX Thoracic Aortic Securement System (K121168)

Submission Summary (Full Text)

{0}------------------------------------------------

WAPTUS
ENDOSYSTEMS

## 510(k) SUMMARY PER 21 CFR 807.92

510(k) Number: K_130677

APR 1 2 2013

#### GENERAL INFORMATION:

#### Manufacturer:

Aptus Endosystems, Inc. 271 Gibraltar Drive Sunnyvale, CA 94089 Tel: [phone] Fax: [phone]

Contact Person:

Burt Goodson Director, Scientific and Regulatory Affairs

Date Prepared:

March 11, 2013

#### DEVICE DESCRIPTION:

The Heli-FX.Aortic Securement System comprises the EndoAnchor with EndoAnchor Cassette, the Heli-FX Applier, and the Heli-FX Guide.

Generic/Common Name and Classification:

Endovascular suturing system (OTD) per 21 CFR 870.3460

Trade Name:

Aptus Heli-FX Aortic Securement System

- . Aptus EndoAnchor with EndoAnchor Cassette
- . Aptus Heli-FX Applier
- . Aptus Heli-FX Guide

#### PREDICATE DEVICES:

- . Aptus Heli-FX Aortic Securement System per K102333
- . Aptus Heli-FX Thoracic Aortic Securement System per K121168

#### INTENDED USE:

The Heli-FX Aortic Securement System is intended to provide fixation and sealing between endovascular aortic grafts and the native artery. The Heli-FX System is indicated for use in

{1}------------------------------------------------

Special 510{k} Submission for Modifications to the Heli-FX Aortic Securement System

patients whose endovascular grafts have exhibited migration or endoleak, or are at risk of such complications, in whom augmented radial fixation and/or sealing is required to regain or maintain adequate aneurysm exclusion.

The EndoAnchor may be implanted at the time of the initial endograft placement, or during a secondary (i.e., repair) procedure.

## PRODUCT DESCRIPTION:

The Heli-FX Aortic Securement System comprises the EndoAnchor implant (an intravascularlyapplied suture, supplied in a Cassette containing 10 EndoAnchors), the Heli-FX Applier (a catheter-based device for placement of the EndoAnchor), and the Heli-FX Guide (a deflectable sheath to position the Applier).

The Aptus EndoAnchor is an endovascularly-placed suture designed to attach aortic endografts to the native vessel wall. The EndoAnchor is manufactured from medical-grade nickel-cobalt wire and is wound in a helical shape. The leading end is sharpened to a conical point to act as an integral needle facilitating atraumatic deployment through the graft material and vessel wall. The proximal end of the EndoAnchor includes a diagonal crossbar, which functions as a suture anchor designed to prevent over penetration of the EndoAnchor. Ten (10) EndoAnchors are pre-packaged into a cassette, which is supplied sterile to the user. The cassette is designed to facilitate easy and accurate loading of the EndoAnchor into the Applier catheter.

The Heli-FX Applier is designed to implant the Aptus EndoAnchor. The Applier implants one EndoAnchor at a time, and can be used to implant multiple EndoAnchors in a single patient. The Applier is designed for use with the Heli-FX Guide. The Applier is a 12Fr (OD) catheter with an integrated control handle. Two Applier lengths are available for anchoring in different regions of the aorta.

The Heli-FX Guide is a sterile, single use, disposable device designed to direct the Heli-FX Applier to the desired location for EndoAnchor implantation. The device is compatible with a 0.035" guide wire. The Heli-FX Guide consists of a 12 Fr-compatible (inner diameter) guide sheath with integrated control handle, and a matching 12 Fr OD obturator. Deflection of the distal tip of the catheter is accomplished by rotating the Control Knob located on the control handle. The Guide is available in both 62cm (16Fr OD) and 90cm (18Fr OD) working lengths. Multiple deflectable tip lengths are available to accommodate a range of aortic diameters. The Obturator is used during vessel access and is designed to follow the guide wire and provide access through tortuous vasculature.

### SPECIAL CONTROLS:

Special controls have been established for endovascular substring systems per 21 CFR 870.3460(b). These special controls include specific requirements related to biocompatibility, sterility and shelf-life, performance testing, MR compatibility, electromagnetic compatibility and electrical safety, labeling, and the prescription-only status of the devices.

{2}------------------------------------------------

Image /page/2/Picture/0 description: The image shows the logo for Aptus Endosystems. The logo consists of a stylized "W" shape followed by the word "APTUS" in bold, sans-serif font. Below "APTUS" is the word "ENDOSYSTEMS" in a smaller, sans-serif font.

### SUBSTANTIAL EQUIVALENCE:

The various components of the Heli-FX System covered in this submission are substantially equivalent in materials, method of operation, and intended use as the prior Heli-FX Systems cleared via K102333 and K121168. Where specific dimensional and performance differences exist, bench testing has shown that these differences do not present new risks.

## DATA RELIED UPON FOR SUBSTANTIAL EQUIVALENCE:

Data relied upon to demonstrate substantial equivalence of the modified Heli-FX System to the predicates, and to demonstrate conformance to special controls, includes the following:

- Performance and simulated use testing
- . Mechanical characterization testing

#### SUMMARY:

The Heli-FX System covered in this submission has been shown to be substantially equivalent to the predicate devices.

{3}------------------------------------------------

#### DEPARTMENT OF HEALTH & HUMAN SERVICES

Image /page/3/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a circular seal with the text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" arranged around the perimeter. Inside the circle is a stylized symbol resembling an eagle or bird in flight, with three curved lines forming the body and wings.

#### April 12, 2013

Aptus Endosystems c/o Mr. Burt Goodson Director, Scientific & Regulatory Affairs 777 North Pastoria Avenue Sunnyvale, CA 94085

Re: K130677

Trade/Device Name: Heli-FX Aortic Securement Systems Regulation Number: 21 CFR 870.3460 Regulation Name: Endovascular Suturing System Regulatory Class: Class II (two) Product Code: OTD Dated: March 11, 2013 . Received: March 14, 2013

Dear Mr. Goodson:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food. Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical

Public Health Service

Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-002

{4}------------------------------------------------

Page 2 - Mr. Burt Goodson

device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices/ucm115809.htm for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to

http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number [phone] or [phone] or at its Internet address

http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.

Sincerely yours,

Matthew G. Hillebrenner

for

i sa

Bram D. Zuckerman, M.D. Director Division of Cardiovascular Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

{5}------------------------------------------------

WAPTUS
ENDOSYSTEMS

Aptus Endosystems, Inc. 271 Gibraltar Dr Sunnyvale, CA 94089

:

·

# STATEMENT OF INDICATIONS FOR USE

| 510(k) Number (if known): | K130677 |
|--------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Device Name: | Heli-FX Aortic Securement System |
| Indications for Use: | The Heli-FX Aortic Securement System is intended to provide fixation and sealing between endovascular aortic grafts and the native artery. The Heli-FX System is indicated for use in patients whose endovascular grafts have exhibited migration or endoleak, or are at risk of such complications, in whom augmented radial fixation and/or sealing is required to regain or maintain adequate aneurysm exclusion.<br>The EndoAnchor may be implanted at the time of the initial endograft placement, or during a secondary (i.e., repair) procedure. |
| Prescription Use | X |
| | or Over-the-counter Use |
| Please Do Not Write Below This Line – Continue On Another Page If Needed | |
| Concurrence of CDRH, Office of Device Evaluation (ODE) | |
| Matthew G.Hillebrenner | |
| Division sign-off<br>Division of Cardiovascular Devices | |
| 510(k) Number: | K130677 |

·

.